Omori K, et al. - In this multicenter, prospective, randomized, open-label, controlled trial, 57 candidates were examined to assess the effectiveness and safety of repaglinide (Repa) vs sulfonylurea (SU) for the treatment of elderly patients with type 2 diabetes. They recorded no significant variation in glycated hemoglobin (HbA1c) between the Repa group and SU group. Without increasing hypoglycemia, higher improvements were seen in glycated albumin (GA) and GA to HbA1c ratio (GA/HbA1c) in the Repa group. They concluded that, in elderly patients, improvement in GA and GA/HbA1c and a positive impact on glucose fluctuation resulted from switching from SU to Repa.